|
CH445129A
(fr)
|
1964-04-29 |
1967-10-15 |
Nestle Sa |
Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
|
|
US3459731A
(en)
|
1966-12-16 |
1969-08-05 |
Corn Products Co |
Cyclodextrin polyethers and their production
|
|
US3426011A
(en)
|
1967-02-13 |
1969-02-04 |
Corn Products Co |
Cyclodextrins with anionic properties
|
|
US3453257A
(en)
|
1967-02-13 |
1969-07-01 |
Corn Products Co |
Cyclodextrin with cationic properties
|
|
US3453259A
(en)
|
1967-03-22 |
1969-07-01 |
Corn Products Co |
Cyclodextrin polyol ethers and their oxidation products
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
WO1986005519A1
(en)
|
1985-03-15 |
1986-09-25 |
James Summerton |
Polynucleotide assay reagent and method
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
EP0786522A2
(en)
|
1992-07-17 |
1997-07-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecules for treatment of stenotic conditions
|
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
|
IL115849A0
(en)
|
1994-11-03 |
1996-01-31 |
Merz & Co Gmbh & Co |
Tangential filtration preparation of liposomal drugs and liposome product thereof
|
|
WO1999042091A2
(en)
|
1998-02-19 |
1999-08-26 |
Massachusetts Institute Of Technology |
Use of polycations as endosomolytic agents
|
|
US6683173B2
(en)
|
1998-04-03 |
2004-01-27 |
Epoch Biosciences, Inc. |
Tm leveling methods
|
|
US7070807B2
(en)
|
1999-12-29 |
2006-07-04 |
Mixson A James |
Branched histidine copolymers and methods for using same
|
|
WO2001047496A1
(en)
|
1999-12-29 |
2001-07-05 |
Mixson A James |
Histidine copolymer and methods for using same
|
|
EP2392660A3
(en)
|
2002-11-25 |
2012-03-28 |
Masafumi Matsuo |
ENA Nucleic Acid Drugs Modifying Splicing in mRNA Precursor
|
|
US7468418B2
(en)
|
2003-04-29 |
2008-12-23 |
Avi Biopharma., Inc. |
Compositions for enhancing transport of molecules into cells
|
|
WO2009005793A2
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
US8299206B2
(en)
|
2007-11-15 |
2012-10-30 |
Avi Biopharma, Inc. |
Method of synthesis of morpholino oligomers
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
ES2607603T3
(es)
|
2010-09-30 |
2017-04-03 |
Nippon Shinyaku Co., Ltd. |
Derivado de ácido morfolino nucleico
|
|
CA3092114A1
(en)
|
2011-05-05 |
2012-11-08 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
CA2861247C
(en)
|
2011-12-28 |
2021-11-16 |
Nippon Shinyaku Co., Ltd. |
Antisense nucleic acids
|
|
US20140315977A1
(en)
*
|
2013-03-14 |
2014-10-23 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
US20140329762A1
(en)
*
|
2013-03-15 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
DK3118311T3
(en)
|
2014-03-12 |
2019-03-11 |
Nippon Shinyaku Co Ltd |
Antisense nucleic acid
|
|
MX373052B
(es)
|
2014-06-17 |
2020-05-11 |
Nippon Shinyaku Co Ltd |
Acidos nucleicos antisentido.
|
|
HUE050061T2
(hu)
|
2015-09-15 |
2020-12-28 |
Nippon Shinyaku Co Ltd |
Antiszensz nukleinsav
|
|
EP3858993A1
(en)
*
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
IL295755A
(en)
|
2015-10-09 |
2022-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
MX2018016253A
(es)
|
2016-07-05 |
2019-09-09 |
Biomarin Tech Bv |
Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
|
|
ES3038159T3
(en)
|
2016-11-16 |
2025-10-09 |
Academisch Ziekenhuis Leiden |
Substances for targeting various selected organs or tissues
|
|
PT3554552T
(pt)
|
2016-12-19 |
2022-10-03 |
Sarepta Therapeutics Inc |
Conjugados de oligómero de skipping de exão para distrofia muscular
|
|
KR102810425B1
(ko)
|
2016-12-19 |
2025-05-21 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
MX2020003130A
(es)
|
2017-09-22 |
2020-09-25 |
Avidity Biosciences Inc |
Composiciones y metodos de induccion de salto de exon en acidos nucleicos-polipeptidos.
|
|
EP3687547A1
(en)
*
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
CN112399849A
(zh)
|
2018-06-26 |
2021-02-23 |
日本新药株式会社 |
含有反义寡核苷酸的组合物及其在迪谢内肌营养不良症的治疗中的用途
|
|
CA3108282A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
SG11202103938UA
(en)
|
2018-11-02 |
2021-05-28 |
Biomarin Tech Bv |
Bispecific antisense oligonucleotides for dystrophin exon skipping
|
|
IL318474A
(en)
*
|
2018-12-13 |
2025-03-01 |
Sarepta Therapeutics Inc |
Axon-skipping oligomer complexes for muscular dystrophy
|
|
CN113660938A
(zh)
|
2019-01-30 |
2021-11-16 |
国立研究开发法人国立精神·神经医疗研究中心 |
核酸递送复合物
|
|
WO2020219820A1
(en)
|
2019-04-25 |
2020-10-29 |
Avidity Biosciences, Inc. |
Nucleic acid compositions and methods of multi-exon skipping
|
|
EP4267191A1
(en)
*
|
2020-12-23 |
2023-11-01 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|